L7 Informatics Stock for Accredited Investors

Biotech / Life Sciences
By UpMarket Research  |  Last updated: July 2026
CEO Vasu Rangadass Founded 2012 HQ Austin, Texas, US

L7 Informatics provides a unified data platform for pharmaceutical, biotech, CDMO, diagnostics, and research organizations.[4] The company says its software removes data silos and creates an AI-ready foundation across R&D and manufacturing workflows.[4]

Access to pre-IPO shares is available to accredited investors through UpMarket.

Latest Price
$71.5M
Series C, Jun 2022, Perplexity
UpMarket Estimate
$64M
Based on UpMarket valuation model

How to Invest in L7 Informatics Through UpMarket

L7 Informatics shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.

Step 01

Verify accredited investor status

Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.

Step 02

Create an UpMarket account

Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.

Step 03

Review available L7 Informatics offerings

Full offering memoranda and risk disclosures provided before any commitment is required.

Step 04

Complete subscription documents

Review and sign subscription agreement. All documents handled digitally through the platform.

Step 05

Fund your investment

Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.

Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.

${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.

Valuation Growth Over Time

Post-money valuation by round
Previous rounds Most recent
DateRoundPPS (split-adj.)Valuation
Jun 2022 Series C $71.5M

L7 Informatics Revenue and Growth

Annual revenue

Why Investors Are Watching L7 Informatics

Growth Signal

L7 Informatics posted 2047% revenue growth over three years

L7 Informatics said it made Deloitte’s Technology Fast 500 for a third straight year, citing 2047% revenue growth over that period. The company also disclosed a $38 million growth investment to expand its precision healthcare platform.

Competitive Moat

L7|ESP positions itself as a unified layer across life sciences systems

L7 says its L7|ESP platform removes data silos across pharma, biotech, CDMO, diagnostics, and research organizations. It links workflows across LIMS, ELN, MES, and scheduling systems while contextualizing data at the source for AI-ready operations.

Market Opportunity

Life sciences platform demand spans research development and manufacturing

L7 says its platform orchestrates workflows across research, development, and manufacturing, targeting organizations that need one operating layer across the full lifecycle. Banneker Partners describes the company as offering both an orchestration layer and discrete applications to improve information flow between process and people.

Interested in L7 Informatics stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.

Request access →

L7 Informatics Leadership Team

Vasu Rangadass
CEO
Trent Carrier
COO

UpMarket Investment Curation Process

  • Full diligence on every offering

    UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.

  • Strategy, fees & legal reviewed in full

    We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.

  • Disciplined managers only

    We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.

  • Built around your objectives

    Our goal is to empower you to build a portfolio that best meets your individual investment objectives.

Ready to access institutional-grade private market investments? Unlock private markets

L7 Informatics Stock FAQ

No. As of March 2026, L7 Informatics is a private company and does not trade on any public stock exchange. Accredited investors can access L7 Informatics shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.

L7 Informatics does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.

Yes. Accredited investors can indicate interest in L7 Informatics shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.

Pre-IPO investments carry significant risks. L7 Informatics shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.

In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.

There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.

The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.

UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.

L7 Informatics provides a unified data platform for pharmaceutical, biotech, CDMO, diagnostics, and research organizations and generated $23.8M in 2024 revenue, with 2047% revenue growth over three years — accredited investors can access L7 Informatics stock through UpMarket.

Invest in L7 Informatics Request access